$Low‐dose rituximab every 6 months for the treatment of acetylcholine receptor–positive refractory generalized myasthenia gravis$

Low‐dose rituximab every 6 months for the treatment of acetylcholine receptor–positive refractory generalized myasthenia gravis

Introduction In this prospective, open‐label study we explore the effectiveness of low‐dose rituximab every 6 months in treating refractory generalized myasthenia gravis (GMG). Methods Twelve patients with acetylcholine receptor (AChR)‐positive refractory GMG were enrolled for the study. The primary...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Muscle & nerve 2020-03, Vol.61 (3), p.311-315
Hauptverfasser:	Lu, Jun, Zhong, Huahua, Jing, Sisi, Wang, Liang, Xi, Jianying, Lu, Jiahong, Zhou, Lei, Zhao, Chongbo
Format:	Artikel
Sprache:	eng
Schlagworte:	AChR Adult Female Humans Immunologic Factors - administration & dosage low dose Male MGFA myasthenia gravis Myasthenia Gravis - blood Myasthenia Gravis - drug therapy Myasthenia Gravis - immunology Prospective Studies Receptors, Cholinergic - blood Receptors, Cholinergic - immunology refractory rituximab Rituximab - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!